Table S1. Alternative Peptide Sequences used in the VAC039 Study. Both the MSP1
and AMA1 bi-valent transgenes consist of composite antigen sequences
2,7
. In this trial,
peptides containing artificial junctions were excluded from the routine peptide pools used
for ELISPOT or ICS assays and/or replaced with shorter peptides stopping at the
junctional sequences. These peptide replacements (in comparison to those used in the
Phase Ia studies) are shown in the Table. 14mer “Junctional” peptides were also designed
to equally span transgene coding sequences containing the junctions where antigen
sequences, that are not sequential in the native protein, have been joined together.
Responses to these de novo epitopes across these peptide junctions will likely represent a
response that would be non-functional in the context of natural antigen (malaria parasite)
exposure.
Peptide Change:
Antigen
AMA1
MSP1
MSP1
MSP1
MSP1
MSP1
MSP1
MSP1
MSP1
MSP1
MSP1
Original
Peptide
Name
A52
M5
M6
M22
M23
M25
M26
M34
M35
M71
M72
Sequence
IPEHKPTYDKMKGGGPGGG
TGYSLFQKEKMVLNELFDLT
MVLNELFDLTNHMLTLCDNI
LEKRIDTLKKNENIKIKEIA
NENIKIKEIAKTIKFNIDSL
FTDPLELEYYLREKNKKMQI
LREKNKKMQIKKLTLLKEQL
KTLSEVSIQTEDNYANLEGQ
EDNYANLEGQVVTGEAVTPS
YPLFDGIFCSSSNGGGPGGG
SSNGGGPGGGDQVVTGEAIS
Replacement
Peptide Name
Sequence
A52#
IPEHKPTYDKMK
M5#
TGYSLFQKEKMVLNE
M6#
LFDLTNHMLTLCDNI
M22#
LEKRIDTLKKNENIK
M23#
IKEIAKTIKFNIDSL
M25#
FTDPLELEYYLREKNK
M26#
KMQIKKLTLLKEQL
M34#
KTLSEVSIQTEDNYANLE
M35#
GQVVTGEAVTPS
M71#
YPLFDGIFCSSSN
Peptide No Longer Required
Junctional Peptides:
Antigen
AMA1
AMA1
AMA1
MSP1
MSP1
MSP1
MSP1
MSP1
MSP1
Peptide Name
tPA/3D7
3D7/Linker
Linker/FVO
JM 1/3
JM 3/5
JM 5/12
JM 12/W33
JM W19/L
JM L/M33
Sequence
HARFRRLDQNYWEH
PTYDKMKGGGPGGG
GGGPGGGQNYWEHP
EKMVLNELFDLTNH
KKNENIKIKEIAKT
YLREKNKKMQIKKL
DNYANLEGQVVTGE
IFCSSSNGGGPGGG
GGGPGGGDQVVTGE